Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

30
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
30
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

28
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
28
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

26
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
26
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Evolution and Validation of Thyroid Cancer Guidelines as Evidence Advances Toward Individualized Therapy.

The Journal of clinical endocrinology and metabolism·2026
Same author

Perioperative nutrition therapy to optimize colorectal patient outcomes: A systematic review and meta-analysis.

JPEN. Journal of parenteral and enteral nutrition·2026
Same author

Factors associated with mortality in pancreatic adenocarcinoma patients achieving pathologic complete response after neoadjuvant therapy.

American journal of surgery·2026
Same author

Association of proximal adenomas with high-grade dysplasia with increased cumulative incidence of postpolypectomy colon cancer: A Surveillance, Epidemiology, and End Results-Medicare analysis.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2026
Same author

Incremental Value of Adherence to Repeat Stool Test in Reducing Long-term Incidence of Colorectal Cancer.

Journal of clinical gastroenterology·2026
Same author

Missing, but not Forgotten: Commission on Cancer Center Accreditation and the Impact of Missing Data in SEER Studies.

Journal of the American College of Surgeons·2026

Related Experiment Video

Updated: Apr 30, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K

Papillary thyroid microcarcinoma: an over-treated malignancy?

Tracy S Wang1, Paolo Goffredo, Julie Ann Sosa

  • 1Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA, tswang@mcw.edu.

World Journal of Surgery
|May 6, 2014
PubMed
Summary
This summary is machine-generated.

Papillary thyroid microcarcinoma (PTMC) treatment in the US shows increasing total thyroidectomy and radioactive iodine (RAI) use. However, survival rates do not differ significantly, suggesting potential overtreatment for many PTMC patients.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K

Related Experiment Videos

Last Updated: Apr 30, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K

Area of Science:

  • Endocrinology
  • Oncology
  • Surgical Oncology

Background:

  • Clinical significance of papillary thyroid microcarcinoma (PTMC) is debated.
  • Current guidelines suggest thyroid lobectomy alone may be sufficient for PTMC.
  • Population-level treatment patterns for PTMC in the USA require examination.

Purpose of the Study:

  • To identify and analyze population-level treatment patterns for PTMC in the USA.
  • To examine demographic, clinical, and pathological characteristics associated with PTMC treatment.
  • To evaluate survival outcomes based on different treatment modalities for PTMC.

Main Methods:

  • Analysis of patients diagnosed with PTMC using the SEER database (1998-2010).
  • Examination of demographic, surgical extent, post-operative radioactive iodine (RAI) administration, and pathological characteristics.
  • Assessment of 5- and 10-year overall survival (OS) and disease-specific survival (DSS).

Main Results:

  • A cohort of 29,512 PTMC patients was analyzed; mean age was 48.5 years, mean tumor size 0.53 cm.
  • Total thyroidectomy (73.4%) and RAI (31.3%) were common; total thyroidectomy more frequent in multifocal or advanced PTMC.
  • No significant difference in DSS between partial and total thyroidectomy; OS similar to the general population.

Conclusions:

  • Increasing trends in total thyroidectomy and RAI for PTMC observed.
  • Potential for overtreatment exists, as many PTMC patients do not show survival benefits from aggressive therapies.
  • Further research may refine treatment guidelines for specific PTMC patient subsets.